Companies in #Obesity

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for obesity and metabolic disease, with a lead asset (ribupatide) targeting GLP-1/GIP dual agonism. The company completed a record-setting IPO in early June 2026 and presented positive Chinese Phase 2 data at the American Diabetes Association conference, positioning it as a notable China-originated obesity biotech in the public markets.

Sciwind Biosciences is a Chinese clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for metabolic disease, with a lead asset in obesity based on a once-monthly GLP-1/glucagon dual agonist formulation. The company has signed two Western licensing deals for its obesity candidate and is open to additional geographic partnerships as it seeks to expand beyond the Chinese market.

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for serious diseases, with a lead program (GSBR-1290) in oral GLP-1 receptor agonism for obesity and type 2 diabetes. The company's pipeline targets GPCR-driven metabolic and cardiopulmonary diseases, leveraging structure-based drug design to create differentiated oral alternatives to injectable peptide therapies.